Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 15, Pages 3697
Publisher
MDPI AG
Online
2021-07-23
DOI
10.3390/cancers13153697
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
- (2021) D. Miles et al. ANNALS OF ONCOLOGY
- Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer
- (2020) Felix Meyer et al. Cells
- Lung Cancer Cells Derived Circulating miR-21 Promotes Differentiation of Monocytes into Osteoclasts
- (2020) Qian Zhao et al. OncoTargets and Therapy
- PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer
- (2020) Haiying Zhu et al. DRUG DISCOVERY TODAY
- Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
- (2020) Lin-Yu Xia et al. World Journal of Surgical Oncology
- Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
- (2020) María G. C. Navarrete-Bernal et al. Frontiers in Oncology
- Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer
- (2020) John M. Seligson et al. ANNALS OF PHARMACOTHERAPY
- Triple‑negative breast cancer therapy: Current and future perspectives (Review)
- (2020) Kwang‑Ai Won et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer
- (2020) Jinhong Shi et al. Cancer Management and Research
- Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
- (2020) Gagan K. Gupta et al. Cancers
- Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
- (2020) Xupeng Bai et al. CANCER LETTERS
- PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers
- (2019) Yanjun Hou et al. HUMAN PATHOLOGY
- Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy
- (2019) Jiabei He et al. Cell Death & Disease
- Targeting Trop-2 in solid tumors: future prospects
- (2019) Saif Zaman et al. OncoTargets and Therapy
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Targeting the PI3-kinase pathway in triple-negative breast cancer
- (2019) J Pascual et al. ANNALS OF ONCOLOGY
- Recent advances in triple negative breast cancer: the immunotherapy era
- (2019) Antonio Marra et al. BMC Medicine
- Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC).
- (2019) Katia Khoury et al. JOURNAL OF CLINICAL ONCOLOGY
- Cyclophosphamide and the taste system: Effects of dose fractionation and amifostine on taste cell renewal
- (2019) Eugene R. Delay et al. PLoS One
- Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
- (2019) Shristi Bhattarai et al. Cancers
- DTL promotes cancer progression by PDCD4 ubiquitin-dependent degradation
- (2019) Haoran Cui et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Radiation treatment in early stage triple‐negative breast cancer in New Zealand: A national database study
- (2019) Ashutosh Dixit et al. Journal of Medical Imaging and Radiation Oncology
- LBA21KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
- (2019) J Cortés et al. ANNALS OF ONCOLOGY
- Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review
- (2019) Jessa Gilda P. Pandy et al. BMC CANCER
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next‑generation sequencing
- (2019) Heming Wu et al. ONCOLOGY REPORTS
- Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights
- (2019) Sonal Patel et al. Frontiers in Immunology
- DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy
- (2018) Cynthia Bernier et al. ANTI-CANCER DRUGS
- Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients
- (2018) Silvana Anna Maria Urru et al. BMC CANCER
- Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
- (2018) Ricardo L. B. Costa et al. BREAST CANCER RESEARCH AND TREATMENT
- Differences in Breast Cancer Survival by Molecular Subtypes in the United States
- (2018) Nadia Howlader et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Cancer stem cell in breast cancer therapeutic resistance
- (2018) Xupeng Bai et al. CANCER TREATMENT REVIEWS
- JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance
- (2018) Tianyi Wang et al. Cell Metabolism
- Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group
- (2018) Emmanouil Saloustros et al. Clinical Breast Cancer
- Alarming Burden of Triple-Negative Breast Cancer in India
- (2018) Krishan K. Thakur et al. Clinical Breast Cancer
- Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
- (2018) Tiffany A. Traina et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer
- (2018) Aurélie S. Cazet et al. Nature Communications
- Buparlisib is a brain penetrable pan-PI3K inhibitor
- (2018) Mark C. de Gooijer et al. Scientific Reports
- Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells
- (2018) Patricia Midori Murobushi Ozawa et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer-associated MORC2 mutant M276I regulates an hnRNPM-mediated CD44 splicing switch to promote invasion and metastasis in triple-negative breast cancer
- (2018) Fang-Lin Zhang et al. CANCER RESEARCH
- ATR inhibition is a promising radiosensitizing strategy for triple negative breast cancer
- (2018) Xinyi Tu et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade
- (2018) Ye Qin et al. ONCOGENE
- Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
- (2018) Ugo Testa et al. Cancers
- Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
- (2018) S Loibl et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy
- (2018) Fouzia Guestini et al. BREAST CANCER RESEARCH AND TREATMENT
- Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy with Bevacizumab and Erlotinib
- (2018) L. Symonds et al. Clinical Breast Cancer
- Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success
- (2018) Amar Desai et al. Stem Cells Translational Medicine
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
- (2017) Tsukasa Shibue et al. Nature Reviews Clinical Oncology
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extracellular Vesicles: Unique Intercellular Delivery Vehicles
- (2017) Sybren L.N. Maas et al. TRENDS IN CELL BIOLOGY
- Chemotherapy-Induced Ca 2+ Release Stimulates Breast Cancer Stem Cell Enrichment
- (2017) Haiquan Lu et al. Cell Reports
- Protein and chemotherapy profiling of extracellular vesicles harvested from therapeutic induced senescent triple negative breast cancer cells
- (2017) E L Kavanagh et al. Oncogenesis
- Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer
- (2017) Miho Kono et al. JAMA Oncology
- Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer
- (2017) Reva K. Basho et al. JAMA Oncology
- Targeting Lung Cancer Stem Cells: Research and Clinical Impacts
- (2017) Norashikin Zakaria et al. Frontiers in Oncology
- Endoplasmic reticulum stress: a novel mechanism and therapeutic target for cardiovascular diseases
- (2016) Mei-qing Liu et al. ACTA PHARMACOLOGICA SINICA
- A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
- (2016) H. Bonnefoi et al. ANNALS OF ONCOLOGY
- The genomic landscape of breast cancer and its interaction with host immunity
- (2016) Stephen Luen et al. BREAST
- Lung cancer stem cells: The root of resistance
- (2016) Lauren MacDonagh et al. CANCER LETTERS
- EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape
- (2016) S.-O. Lim et al. CANCER RESEARCH
- Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
- (2016) E. T. Rodler et al. CLINICAL CANCER RESEARCH
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- Features of triple-negative breast cancer
- (2016) Magdalena L. Plasilova et al. MEDICINE
- Exosomal Annexin II Promotes Angiogenesis and Breast Cancer Metastasis
- (2016) Sayantan Maji et al. MOLECULAR CANCER RESEARCH
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways
- (2016) Gemma Leon et al. PHARMACOLOGY & THERAPEUTICS
- Dual Action Enhancement of Gold Nanoparticle Radiosensitization by Pentamidine in Triple Negative Breast Cancer
- (2016) Sohyoung Her et al. RADIATION RESEARCH
- The Warburg Effect: How Does it Benefit Cancer Cells?
- (2016) Maria V. Liberti et al. TRENDS IN BIOCHEMICAL SCIENCES
- Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
- (2016) Katsuhiko Nakatsukasa et al. Breast Cancer
- Landscape of Neoadjuvant Therapy for Breast Cancer
- (2015) Tufia C. Haddad et al. ANNALS OF SURGICAL ONCOLOGY
- Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India
- (2015) Dinesh Chandra Doval et al. Asian Pacific Journal of Cancer Prevention
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance
- (2015) David Westover et al. Molecular Cancer
- Molecular characteristics of recurrent triple-negative breast cancer
- (2015) CHUNG-HSIN TSAI et al. Molecular Medicine Reports
- Targeting the TGFβ pathway for cancer therapy
- (2015) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
- (2015) Haiquan Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
- (2015) Murugan Kalimutho et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy
- (2015) Chi Zhang et al. SpringerPlus
- Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
- (2015) Giuseppina Rosaria Rita Ricciardi et al. PLoS One
- Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years
- (2014) Masaaki Kawai et al. CANCER
- Oral Contraceptives and Breast Cancer Risk Overall and by Molecular Subtype Among Young Women
- (2014) E. F. Beaber et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Enriched CD44+/CD24− population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC)
- (2014) Fei Ma et al. CANCER LETTERS
- Hallmarks of triple negative breast cancer emerging at last?
- (2014) Rosa Bernardi et al. CELL RESEARCH
- Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer
- (2014) Jian Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
- (2014) Jordi Rodon et al. INVESTIGATIONAL NEW DRUGS
- Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study
- (2014) Mary-Ellen Taplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
- (2014) EBCTCG (Early Breast Cancer Trialists' Collaborative Group) LANCET
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry
- (2014) Abenaa M Brewster et al. LANCET ONCOLOGY
- High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation
- (2014) Guizhi Dong et al. MEDICAL ONCOLOGY
- Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance
- (2014) Antonina V. Kurtova et al. NATURE
- Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells
- (2014) Debangshu Samanta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein
- (2014) Meng-meng Lv et al. TUMOR BIOLOGY
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
- (2013) D. W. Miles et al. ANNALS OF ONCOLOGY
- Outcomes of Delays in Time to Treatment in Triple Negative Breast Cancer
- (2013) Amy Eastman et al. ANNALS OF SURGICAL ONCOLOGY
- High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival
- (2013) Akimitsu Yamada et al. BREAST CANCER RESEARCH AND TREATMENT
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
- (2013) H. Masuda et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- Nonclassical Activation of Hedgehog Signaling Enhances Multidrug Resistance and Makes Cancer Cells Refractory to Smoothened-targeting Hedgehog Inhibition
- (2013) Shamik Das et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
- (2013) Neil E. Bhola et al. JOURNAL OF CLINICAL INVESTIGATION
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
- (2013) Andrew M. Intlekofer et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Lung cancer stem cells: Molecular features and therapeutic targets
- (2013) Sandeep Singh et al. MOLECULAR ASPECTS OF MEDICINE
- Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
- (2013) Seung Woo Cho et al. NATURE BIOTECHNOLOGY
- BEATRICE bevacizumab trial—every cloud has a silver lining
- (2013) Lisa Hutchinson Nature Reviews Clinical Oncology
- Identification of annexin II as a novel secretory biomarker for breast cancer
- (2013) You Rim Jeon et al. PROTEOMICS
- Landmark Trials Affecting the Surgical Management of Invasive Breast Cancer
- (2013) Dalliah M. Black et al. SURGICAL CLINICS OF NORTH AMERICA
- DNA Damage Sensing by the ATM and ATR Kinases
- (2013) A. Marechal et al. Cold Spring Harbor Perspectives in Biology
- Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation
- (2013) A Notte et al. Cell Death & Disease
- Loss of O6-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells
- (2012) Selina Raguz et al. BIOCHEMICAL PHARMACOLOGY
- Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients
- (2012) Caterina Fumagalli et al. BREAST CANCER RESEARCH AND TREATMENT
- Breast cancer, side population cells and ABCG2 expression
- (2012) K.M. Britton et al. CANCER LETTERS
- The association of annexin A2 and cancers
- (2012) Xiaohui Zhang et al. Clinical & Translational Oncology
- Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies
- (2012) Laleh Amiri-Kordestani et al. DRUG RESISTANCE UPDATES
- A metabolic prosurvival role for PML in breast cancer
- (2012) Arkaitz Carracedo et al. JOURNAL OF CLINICAL INVESTIGATION
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes
- (2012) Claire Corcoran et al. PLoS One
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Beclin 1 deficiency is associated with increased hypoxia-induced angiogenesis
- (2011) Seon-Jin Lee et al. Autophagy
- A microRNA expression signature of osteoclastogenesis
- (2011) T. Sugatani et al. BLOOD
- Higher population-based incidence rates of triple-negative breast cancer among young African-American women
- (2011) Kathryn C. Amirikia et al. CANCER
- Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer
- (2011) Ana P. Kiess et al. CANCER
- Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women
- (2011) Geoffrey C. Kabat et al. CANCER CAUSES & CONTROL
- TGF /TNF -Mediated Epithelial-Mesenchymal Transition Generates Breast Cancer Stem Cells with a Claudin-Low Phenotype
- (2011) M. K. Asiedu et al. CANCER RESEARCH
- Microvesicles Released from Human Renal Cancer Stem Cells Stimulate Angiogenesis and Formation of Lung Premetastatic Niche
- (2011) C. Grange et al. CANCER RESEARCH
- Oral contraceptive formulation and risk of breast cancer
- (2011) Polly A. Marchbanks et al. CONTRACEPTION
- Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies
- (2011) Laura Vera-Ramirez et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Stromal–epithelial metabolic coupling in cancer: Integrating autophagy and metabolism in the tumor microenvironment
- (2011) Ubaldo E. Martinez-Outschoorn et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance
- (2011) Rabab A A Mohammed et al. MODERN PATHOLOGY
- Triple-Negative Breast Cancer: An Unmet Medical Need
- (2011) C. A. Hudis et al. ONCOLOGIST
- Alteration of REDD1-Mediated Mammalian Target of Rapamycin Pathway and Hypoxia-Inducible Factor-1α Regulation in Human Breast Cancer
- (2011) Ja Seung Koo et al. PATHOBIOLOGY
- The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts
- (2011) Héctor Peinado et al. SEMINARS IN CANCER BIOLOGY
- Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy
- (2011) Hiroshi Yagata et al. Breast Cancer
- Triple-Negative Breast Cancer
- (2010) Anthony D. Elias AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Triple-Negative Breast Cancer
- (2010) Steven J. Isakoff CANCER JOURNAL
- Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation
- (2010) J. A. Bauer et al. CLINICAL CANCER RESEARCH
- Heterogeneity for Stem Cell-Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer
- (2010) S. Y. Park et al. CLINICAL CANCER RESEARCH
- Triple-Negative Breast Cancer
- (2010) Shaheenah Dawood DRUGS
- MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC
- (2010) Christian Busch et al. EUROPEAN JOURNAL OF CANCER
- Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials
- (2010) Nicolai Juul et al. LANCET ONCOLOGY
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pdcd4 repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion
- (2010) A N Santhanam et al. ONCOGENE
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
- (2010) A Singh et al. ONCOGENE
- Recent advances in large-scale production of monoclonal antibodies and related proteins
- (2010) Abhinav A. Shukla et al. TRENDS IN BIOTECHNOLOGY
- Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
- (2009) B. K. Linderholm et al. ANNALS OF ONCOLOGY
- Triple-negative breast cancer--current status and future directions
- (2009) O. Gluz et al. ANNALS OF ONCOLOGY
- Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer
- (2009) Miguel Martín et al. BREAST CANCER RESEARCH AND TREATMENT
- Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
- (2009) J Dunn et al. BRITISH JOURNAL OF CANCER
- The epidemiology of triple-negative breast cancer, including race
- (2009) Katrina F. Trivers et al. CANCER CAUSES & CONTROL
- Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years
- (2009) J. M. Dolle et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Membrane Microvesicles as Actors in the Establishment of a Favorable Prostatic Tumoral Niche: A Role for Activated Fibroblasts and CX3CL1-CX3CR1 Axis
- (2009) D. Castellana et al. CANCER RESEARCH
- Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
- (2009) Farrah Kassam et al. Clinical Breast Cancer
- Variation in breast cancer subtypes with age and race/ethnicity
- (2009) Carol A. Parise et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations
- (2009) Jeung Il Kim et al. HUMAN PATHOLOGY
- Lung cancer secreted microvesicles: Underappreciated modulators of microenvironment in expanding tumors
- (2009) Marcin Wysoczynski et al. INTERNATIONAL JOURNAL OF CANCER
- Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide
- (2009) Martin Glas et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed cell death 4 (PDCD4) suppresses metastastic potential of human hepatocellular carcinoma cells
- (2009) Shuhong Zhang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Pharmacogenetics of Membrane Transporters: An Update on Current Approaches
- (2009) Tristan M. Sissung et al. MOLECULAR BIOTECHNOLOGY
- Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer
- (2009) Na Wei et al. Molecular Cancer
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
- (2009) C. J. Creighton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Triple-Negative Breast Cancer: Correlation between MR Imaging and Pathologic Findings
- (2009) Takayoshi Uematsu et al. RADIOLOGY
- Programmed Cell Death 4 inhibits breast cancer cell invasion by increasing Tissue Inhibitor of Metalloproteinases-2 expression
- (2008) René Nieves-Alicea et al. BREAST CANCER RESEARCH AND TREATMENT
- Early onset of breast cancer in a group of British black women
- (2008) R L Bowen et al. BRITISH JOURNAL OF CANCER
- Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
- (2008) M. C.U. Cheang et al. CLINICAL CANCER RESEARCH
- O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
- (2008) M. H. Kulke et al. CLINICAL CANCER RESEARCH
- miR-21: a small multi-faceted RNA
- (2008) Anna M. Krichevsky et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer
- (2008) Deann P. Atchley et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2008) I. J. Dahabreh et al. ONCOLOGIST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation